secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2026-06-11T20:43:01+00:00
Accession:  0001104659-26-072980
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte prices $50M public offering of 47.6M shares at $1.05 per share
-----------------------------------------------------------------------

- Sold 47,619,048 shares at $1.05/share; gross proceeds ~$50M.
- Net proceeds expected ~$46.8M (~$53.85M if underwriters exercise 30-day over-allotment of 7,142,857 shares).
- Proceeds to fund Symvess commercialization, BLA supplement for hemodialysis, pipeline development, and working capital.
- Offering expected to close June 12, 2026; joint book-runners: Barclays, BTIG, Titan Partners.
- 30-day underwriter option for additional 15% of shares at same price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926072980/0001104659-26-072980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926072980/tm2617224d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-072980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer